GlassScriptPhysician profile
Gautam Ramesh
NPI 1568029361
$1,849.16
in general payments reported to CMS, 2019-2025
21 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2020: $18.09 · 2021: $486 · 2022: $592 · 2023: $326 · 2024: $50.56 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $526.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $270.37 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $217.18 | 2021-2022 | |
| Genzyme Corporation | $206.69 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $146.34 | 2021 | |
| Allergan, INC. | $143.08 | 2019-2020 | |
| Emd Serono, INC. | $124.99 | 2023 | Mavenclad |
| Sanofi-Aventis U.S. LLC | $122.03 | 2021 | |
| Horizon Therapeutics Plc | $121.83 | 2022 | |
| Mdd US Operations, LLC | $117.51 | 2023 | Apokyn |
| Novo Nordisk INC | $74.41 | 2022 | |
| Jazz Pharmaceuticals INC. | $50.65 | 2024-2025 | |
| Inspire Medical Systems, INC. | $45.19 | 2024-2025 | Inspire |
| Avadel Cns Pharmaceuticals, LLC | $31.94 | 2025 | Lumryz |
| Grifols USA, LLC | $28.94 | 2025 | Prolastin-C Liquid |
| United Therapeutics Corporation | $26.65 | 2025 | Tyvaso |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $24.52 | 2023 | Briviact |
| Ipsen Biopharmaceuticals, INC | $24.37 | 2023 | Dysport |
| Alexion Pharmaceuticals, INC. | $20.54 | 2023 | Ultomiris |
| Amgen INC. | $20.46 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $16.95 | 2025 | Farxiga |
| Abbvie INC. | $14.52 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gautam Ramesh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.